AI assistant
Probi — Interim / Quarterly Report 2023
Apr 26, 2023
3099_10-q_2023-04-26_69592a40-d6b6-440e-b564-5a70a9582a4b.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer

- Net sales increased by 11% (2% adjusted for currency effects) to SEK 172 m (155).
- The EBITDA margin amounted to 28% (25).
- Positive one-off effects totaling SEK 18 m regarding postponed orders from Q4 2022.
- Takeover of the distribution of our own brand Probi® in Sweden from April 1, 2023. New market organization established.
- First commercial batch of spores produced.
- Anita Johansen appointed CEO of Probi on March 30. Von Carlson took over as the new VP of Operations on March 27.

| Jan-Mar | Full-year | |||
|---|---|---|---|---|
| SEK m | 2023 | 2022 | RTM | 2022 |
| Net sales | 171.8 | 154.7 | 635.4 | 618.3 |
| Growth, % | 11.1% | -9.7% | 2.8% | -6.1% |
| Currency adjusted growth, % | 2.1% | -16.2% | -9.0% | -16.7% |
| Gross margin, % | 42.5% | 42.6% | 41.3% | 41.3% |
| EBITDA | 47.3 | 38.3 | 145.2 | 136.3 |
| EBITDA margin, % | 27.5% | 24.7% | 22.9% | 22.0% |
| Operating profit (EBIT) | 23.6 | 18.5 | 55.7 | 50.6 |
| EBIT margin, % | 13.7% | 12.0% | 8.8% | 8.2% |
| Net income | 19.3 | 14.0 | 45.9 | 40.6 |
| Earnings per share before and after dilution, SEK | 1.69 | 1.23 | 4.03 | 3.57 |
See note 5 for definitions of ratios not defined according to IFRS
This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The Information was submitted for publication, through the agency of the CEO and CFO, on April 26, 2023 at 08:00 CET. This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.


With good help from exchange rates and one-off effects, we started the year with growth of 11% and an EBITDA margin of 28%. Growth amounted to 2% adjusted for currency effects, and postponed orders from Q4 had a one-off effect of SEK 18 m. Sales in the various regions have varied greatly during the quarter and do not provide a fully representative picture of the underlying position. Our assessment is that net sales for the first half of the year will be on par with or slightly below last year.
During Q1, the EMEA region was impacted by sell-out of stock by our former distributor in Sweden, affecting net sales, and decreasing in total in the region by 33% compared to the previous year. From April 1, we will distribute our own brand Probi® in Sweden. We have received a very good response so far and are satisfied with the contract negotiations that have been completed. Our sales are expected to pick up at the end of Q2, as a number of customers have purchased safety stock in connection with this transition. In general there is a certain cautiousness in the EMEA region's markets, but at the same time it is a stable region consisting of many longterm contract customers.
The APAC region delivered its strongest ever quarter with growth of 55%. At the same time, the fluctuations between the quarters are high and our assessment is that net sales will be at last year's level for the first six months. The growth potential in the region remains high with China as the driving force expanding its share of the region's sales even though Australia remains the largest market.
In the Americas region, we increased net sales by 18% during Q1, driven by currency effects and the postponed orders of SEK 18 m from Q4. Adjusted for this, growth was negative. The underlying development is mainly due to a slowdown in the market, where we saw a lower order frequency from our customers.
I was appointed CEO of Probi on March 30, which is a huge honor. At the same time, it means that we will start recruiting a new VP R&D. During Q1, we also strengthened management with a new VP of Operations, Von Carlson. He has a solid background in the production of probiotics from several companies, including DuPont Biosciences. After a couple of years of major investments in our manufacturing, we are entering a new phase where one of Von's most important missions will be to optimize our internal processes to increase efficiency. Against the background of our weak sales trend, we are also reviewing how we best meet our customers' needs and how we can become more efficient internally.
The results of our Gut-brain study are being finalized for publication. In dialogue with our customers, we have noted significant interest in this area and the publication of the study will give us the scientific support to be able to launch a new Gut-brain product, which we plan to do in the autumn.
We have not lived up to our goals and at the same time find ourselves in a challenging period. It is my top priority to get Probi back on the path to growth. Together with my management, I will invest a lot of time in improving our own processes and working methods. It will show us the way back to growth.
Anita Johansen CEO


Interim report January-March 2023
During Q1, net sales amounted to SEK 171.8 m (154.7), which corresponded to an increase of SEK 17.1 m or 11%. Adjusted for currency effects, net sales amounted to SEK 158.0 m, corresponding to an increase of 2%.
The increase of SEK 17.1 m is explained by higher sales in the Americas, which increased by SEK 19.7 m (18%) and APAC, which increased by SEK 7.5 m (55%). EMEA decreased by SEK 10.0 m (-33%).
The share of total net sales in the Americas during Q1 was 76%. EMEA accounted for 12% and APAC 12%.

| Jan-Mar | |||
|---|---|---|---|
| SEK m | 2023 | 2022 | Change, % |
| Americas | 130.7 | 111.0 | 17.7% |
| EMEA | 20.0 | 30.0 | -33.3% |
| APAC | 21.2 | 13.7 | 54.7% |
| Net sales | 171.8 | 154.7 | 11.1% |


The operating profit for the quarter was SEK 23.6 m (18.5), which corresponded to an increase of SEK 5.1 m or 28%. Adjusted for currency effects, the operating profit was SEK 20.3 m. The improved operating profit was mainly due to higher sales.
Sales and marketing expenses amounted to SEK 26.3 m (23.4), with the increase explained by currency effects but also by an increase in costs in connection with the takeover of distribution in Sweden.
Research and development costs were at the previous year's level and amounted to SEK 9.7 m (9.2).
Administrative expenses decreased by SEK 1.5 m compared to last year and amounted to SEK 13.4 m (14.9). This reduction is mainly due to lower costs for personnel and business development.
| Jan-Mar | |||
|---|---|---|---|
| SEK m | 2023 | 2022 | Change, % |
| Gross profit Americas | 48.1 | 39.5 | 21.8% |
| Gross profit EMEA | 11.0 | 17.5 | -37.1% |
| Gross profit APAC | 13.9 | 8.9 | 56.2% |
| Gross profit | 73.0 | 65.9 | 10.8% |
| Sales and marketing expenses | -26.3 | -23.4 | 12.4% |
| Research and development expenses | -9.7 | -9.2 | 5.4% |
| Administration expenses | -13.4 | -14.9 | -10.1% |
| Other operating income | 0.0 | 0.1 | 0.0% |
| Operating profit (EBIT) | 23.6 | 18.5 | 27.6% |
The financial result for Q1 amounted to SEK 0.5 m (-0.9). Net financial items excluding exchange rate results amounted to SEK 0.8 m (-0.6) and consisted mainly of interest on leasing contracts. The exchange rate result amounted to SEK -0.3 m (-0.3) in Q1 and refers to the conversion of cash and cash equivalents into foreign currency.
The period's profit for the quarter amounted to SEK 19.3 m (14.0). Tax costs were SEK 4.8 m (3.6).
Earnings per share for the quarter amounted to SEK 1.69 (1.23).


Probi's operating segments are based on a geographical division and consist of the Americas (North and South America), EMEA (Europe, the Middle East and Africa) and APAC (Asia and the Pacific).
Net sales in the Americas increased by 18% and amounted to SEK 131 m. Adjusted for currency effects net sales amounted to SEK 118 m, corresponding to an increase of 6% during the quarter. There was a positive effect on net sales from postponed orders from Q4, corresponding to SEK 18 m.
The market was characterized by a certain slowdown and a lower order frequency among customers.
The gross margin in Q1 was 37% (36). The slightly improved gross margin is explained by higher sales volumes.
| Jan-Mar | |||
|---|---|---|---|
| SEK m | 2023 | 2022 | Change, % |
| Net Sales | 130.7 | 111.0 | 17.7% |
| Cost of goods sold | -82.6 | -71.5 | 15.5% |
| Gross profit | 48.1 | 39.5 | 21.8% |
| Gross margin | 36.8% | 35.6% | 1.2 ppt |
Net sales in EMEA decreased by 33% in Q1 to SEK 20 m compared to SEK 30 m last year. Q1 was marked by our former distributor in Sweden selling off stock in connection as Probi took over the distribution of its own brand on the Swedish market. Sales are expected to pick up at the end of Q2, where a number of customers have purchased safety stock due to the transition.
The European market was characterized by a certain caution. At the same time, EMEA is a market with contract customers with long contracts, which provides stability.
The gross margin for Q1 was 55% (58). The lower margin is explained by reduced sales volumes.
| Jan-Mar | |||
|---|---|---|---|
| SEK m | 2023 | 2022 | Change, % |
| Net Sales | 20.0 | 30.0 | -33.3% |
| Cost of goods sold | -9.0 | -12.5 | -28.0% |
| Gross profit | 11.0 | 17.5 | -37.1% |
| Gross margin | 55.3% | 58.3% | -3.0 ppt |


Net sales in APAC were the highest ever and amounted to SEK 21 m, which corresponds to an increase of 55% compared to the previous year.
China is the driving force in the region and has greatly increased its share of sales. During Q1 we delivered our first order of BLIS to the Chinese market. Australia continues to be the region's largest market. The region is still characterized by major fluctuations and the assessment is that the net sales in the first half of the year will be on a par with last year.
The gross margin was in principle at the same level as last year and was 66% (65).
| Jan-Mar | |||
|---|---|---|---|
| SEK m | 2023 | 2022 | Change, % |
| Net Sales | 21.2 | 13.7 | 54.7% |
| Cost of goods sold | -7.3 | -4.8 | 52.1% |
| Gross profit | 13.9 | 8.9 | 56.2% |
| Gross margin | 65.8% | 65.0% | 0.8 ppt |
Cash flow from operating activities before changes in working capital increased to SEK 47.0 m (38.8) in Q1 as a result of a higher operating profit.
Working capital increased during Q1 as a result of increased accounts receivable and a greater inventory, and cash flow from operating activities was SEK 12.8 m (37.9).
Cash flow from investment activities was SEK -14.3 m (-15.7) and mainly consisted of investments in tangible and intangible assets.
Cash flow from financing activities was SEK -3.8 m (-3.8) and mainly consisted of the amortization of leasing liabilities.
At the end of the period, cash flow amounted to SEK -5.8 m (20.2) and cash and cash equivalents amounted to SEK 318.0 m (271.2).
During Q1, investments in intangible fixed assets amounted to SEK 4.8 m (2.2), of which SEK 0.8 m (1.4) related to patents, SEK 1.8 m (0.8) related to capitalized development expenses and SEK 2.2 m (0.0) referred to IT systems. Investments in tangible fixed assets amounted to SEK 9.6 m (13.4), which mainly related to investments in the manufacturing unit at Redmond.
At the end of the period, Probi had 172 (176) employees, of which 52% (52) were women. The average number of employees during Q1 amounted to 163 (174).


During Q1, Probi reported SEK 0.0 m (0.6) in revenue from its largest shareholder, Symrise, and costs amounted to SEK 0.0 m (0.0). No other transactions with related parties occurred during the reporting period.
In February 2022, Russia launched an invasion of Ukraine. Probi has a limited exposure to Russia and Ukraine, and the company's assessment is that the effects at both supplier and customer levels are limited. The cost increases that have arisen in connection with increased inflation are mainly compensated by price increases to the customer. However, there may be a delayed effect until the price increases take full effect depending on the agreed terms.
In connection with Covid-19, it is mainly the risks surrounding changing consumer trends and the company's supply of goods that have become relevant. Other risks and uncertainty factors to which Probi's operations are exposed are described on pages 48–49 of the annual report for 2022.
During Q1, the parent company's operating income amounted to SEK 82.0 m (73.4). The profit for the period amounted to SEK 28.8 m (12.3) and this increase was due to a higher operating profit and an improved financial result. Investments in tangible and intangible assets amounted to SEK 2.9 m (5.1). For further details, please see the information for the Group.
| Annual General Meeting 2023 | May 4, 2023 |
|---|---|
| Record date for dividend | May 8, 2023 |
| Payment date for dividend | May 11, 2023 |
| Interim report Q2 2023 | July 18, 2023 |
| Interim report Q3 2023 | October 24, 2023 |
| Year-end report 2023 | January 26, 2024 |
Probi's interim report for Q1 2023 will be published on April 26, 2023, at 8:00 a.m. On the same day at 10:00 a.m., a telephone conference will be held with Anita Johansen, CEO and Henrik Lundkvist, CFO, who will present the report. The telephone conference can be accessed via the link
https://conference.financialhearings.com/teleconference/?id=200639. The presentation is available at www.probi.com and www.financialhearings.com.
Anita Johansen, CEO Telephone: +46 (0)46 286 89 48 E-mail: [email protected] Henrik Lundkvist, CFO Telephone: +46 (0)46 286 89 41 E-mail: [email protected]


The Board of Directors and CEO declare that this interim report provides a true and fair overview of the parent company's and Group's operations, financial position and results, and describes the significant risks and uncertainties facing the parent company and the Group.
Lund, April 26, 2023
Jean-Yves Parisot Chairman of the Board Jörn Andreas Board member
Irène Corthésy Malnoë Board member
Charlotte Hansson Board member
Malin Ruijsenaars Board member
Anita Johansen CEO
This interim report has not been subject to review by the company's auditors.


| Jan-Mar | |||
|---|---|---|---|
| SEK 000 | Notes | 2023 | 2022 |
| Net sales | 2 | 171,819 | 154,718 |
| Cost of goods sold | 3 | -98,815 | -88,817 |
| Gross profit | 73,004 | 65,901 | |
| Sales and marketing expenses | -26,306 | -23,394 | |
| Research and development expenses | -9,721 | -9,203 | |
| Administration expenses | -13,397 | -14,896 | |
| Other operating income | — | 83 | |
| Operating profit (EBIT) | 23,580 | 18,491 | |
| Financial income | 1,391 | 45 | |
| Financial expenses | -543 | -624 | |
| Exchange result financing activities | 4 | -348 | -286 |
| Financial result | 500 | -865 | |
| Earnings before income taxes | 24,080 | 17,626 | |
| Income taxes | -4,806 | -3,607 | |
| Net income | 19,274 | 14,019 | |
| Other comprehensive income | |||
| Components to be reclassified to net income | |||
| Exchange rate differences resulting from the translation of foreign operations | -7,999 | 22,542 | |
| Cash flow hedge (currency hedges) | — | — | |
| Income taxes payable on these components | — | — | |
| Total components to be reclassified to net income | -7,999 | 22,542 | |
| Components not to be reclassified to net income | |||
| Equity instruments at fair value through OCI | 3,732 | -4,328 | |
| Total components not to be reclassified to net income | 3,732 | -4,328 | |
| Sum of other comprehensive income | -4,267 | 18,214 | |
| Total comprehensive income | 15,007 | 32,233 | |
| Number of outstanding shares at end of the reporting period | 11,394,125 | 11,394,125 | |
| Average number of shares | 11,394,125 | 11,394,125 | |
| Earnings per share before and after dilution | 1.69 | 1.23 |
The period's results as well as comprehensive income is attributable in its entirety to the parent company's shareholders. There is no dilution effect, as the company has no outstanding convertible loans or warrants.


Interim report January-March 2023
| SEK 000 | 31 December | 31 December |
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Capitalized development cost | 24,264 | 24,782 |
| Customer base | 239,429 | 248,452 |
| Technology and other intangible assets | 104,692 | 109,251 |
| Goodwill | 351,088 | 353,887 |
| Property, plant and equipment Right-of-use assets |
151,625 61,383 |
146,806 65,546 |
| Interests in other entities | 84,242 | 80,510 |
| Deferred tax assets | 339 | 357 |
| Non-current assets | 1,017,062 | 1,029,591 |
| Inventories | 127,994 | 116,245 |
| Trade receivables | 115,539 | 89,295 |
| Other assets and receivables | 11,647 | 11,051 |
| Cash and cash equivalents | 317,955 | 323,706 |
| Current assets | 573,135 | 540,297 |
| Total assets | 1,590,197 | 1,569,888 |
| EQUITY AND LIABILITIES | ||
| Total equity | 1,425,575 | 1,410,567 |
| Deferred tax liabilities | 11,822 | 13,833 |
| Provisions | 11,822 | 13,833 |
| Non-current lease liabilities | 49,511 | 53,601 |
| Other non-current liabilities | 5,436 | 5,480 |
| Non-current liabilities | 54,947 | 59,081 |
| Trade payables | 47,864 | 34,424 |
| Current lease liabilities | 16,670 | 16,667 |
| Other current liabilities | 33,319 | 35,316 |
| Current liabilities | 97,853 | 86,407 |
| Total liabilities | 164,622 | 159,321 |
| Total equity and liabilities | 1,590,197 | 1,569,888 |


| SEK 000 | Share capital |
Other contri butions received |
Cumulative translation differences |
Hedging reserve |
Fair value reserve |
Accumulat ed profit |
Total equity |
|---|---|---|---|---|---|---|---|
| Opening balance, 1 Jan 2022 | 58,221 | 600,205 | 29,414 | — | -7721 | 585,422 | 1,265,541 |
| Net income | — | — | — | — | — | 14,019 | 14,019 |
| Other comprehensive income | — | — | 22,542 | — | -4,328 | — | 18,214 |
| Total Comprehensive Income | — | — | 22,542 | — | -4,328 | 14,019 | 32,233 |
| Dividends | — | — | — | — | — | — | — |
| Total transactions with shareholders |
— | — | — | — | — | — | — |
| Closing balance, 31 Mar 2022 | 58,221 | 600,205 | 51,956 | — | -12,049 | 599,441 | 1,297,774 |
| SEK 000 | Share capital |
Other contri butions received |
Cumulative translation differences |
Hedging reserve |
Fair value reserve |
Accumulat ed profit |
Total equity |
|---|---|---|---|---|---|---|---|
| Opening balance, 1 Jan 2023 | 58,221 | 600,205 | 169,322 | — | -28,412 | 611,232 | 1,410,567 |
| Net income | — | — | — | — | — | 19,274 | 19,274 |
| Other comprehensive income | — | — | -7,999 | — | 3,732 | — | -4,267 |
| Total Comprehensive Income | — | — | -7,999 | — | 3,732 | 19,274 | 15,007 |
| Dividends | — | — | — | — | — | — | — |
| Total transactions with shareholders |
— | — | — | — | — | — | — |
| Closing balance, 31 Mar 2023 | 58,221 | 600,205 | 161,323 | — | -24,680 | 630,506 | 1,425,575 |


| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Net income | 19,274 | 14,019 |
| Adjustments to reconcile net income to cash from | ||
| operating activities | ||
| Income taxes | 4,806 | 3,607 |
| Interest result | -849 | 559 |
| Amortization, depreciation and impairment of non-current assets | 23,686 | 19,787 |
| Other non-cash expenses and income | 42 | 871 |
| Cash flow before working capital changes | 46,959 | 38,843 |
| Change in trade receivables and other current assets | -28,133 | 29,832 |
| Change in inventories | -12,694 | -11,716 |
| Change in trade payables and other current liabilities | 10,980 | -12,253 |
| Income taxes paid | -4,323 | -6,793 |
| Cash flow from operating activities | 12,789 | 37,913 |
| Payments for investing in intangible assets | -4,753 | -2,233 |
| Payments for investing in property, plant and equipment | -9,585 | -13,430 |
| Divestments of tangible assets | — | — |
| Cash flow from investing activities | -14,338 | -15,663 |
| Interest paid | -553 | -612 |
| Interest received | 431 | 1 |
| Repayments for lease obligations | -3,681 | -3,229 |
| Dividends paid | — | — |
| Cash flow from financing activities | -3,803 | -3,840 |
| Cash flow for the period | -5,352 | 18,410 |
| Effects of changes in exchange rates | -399 | 1,769 |
| Change in cash and cash equivalents | -5,751 | 20,179 |
| Cash and cash equivalents at opening balance | 323,706 | 251,017 |
| Cash and cash equivalents at closing balance | 317,955 | 271,196 |


| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Operating revenue | 82,011 | 73,448 |
| Operating costs | -18,850 | -19,340 |
| Gross profit | 63,161 | 54,108 |
| Operating profit (EBIT) | 31,199 | 21,351 |
| Result from financial income and expenses | 4,266 | -4,578 |
| Income before tax | 35,465 | 16,773 |
| Net income | 28,818 | 12,312 |
| Jan-Mar | ||||
|---|---|---|---|---|
| SEK 000 | 2023 | 2022 | ||
| Net income | 28,818 | 12,312 | ||
| Sum of other comprehensive income | — | — | ||
| Total comprehensive income | 28,818 | 12,312 |
| SEK 000 | 31 December 2023 |
31 December 2022 |
|---|---|---|
| ASSETS | ||
| Non-current assets | 1,044,916 | 1,042,975 |
| Current assets | 320,849 | 299,369 |
| Total assets | 1,365,765 | 1,342,344 |
| EQUITY AND LIABILITIES | ||
| Equity | 1,329,349 | 1,300,531 |
| Current liabilities | 36,416 | 41,813 |
| Total equity and liabilities | 1,365,765 | 1,342,344 |


This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The condensed financial statements in the interim report are covered on pages 10-17. Disclosures in accordance with IAS 34 Interim Financial Reporting are provided both here and elsewhere in theinterim report. The ESMA guidelines on alternative performance measures apply.
The accounting principles applied when these consolidated accounts were prepared have been applied consistently for all periods presented, unless otherwise stated. Complete accounting principles can be found on pages 65–68 of the annual report for 2022.
The parent company's functional currency is Swedish kronor (SEK), which is also the reporting currency for both the parent company and the Group. All amounts stated are rounded to the nearest thousand kronor unless otherwise stated.
Amounts and figures in parentheses refer to comparative figures for the corresponding period of the previous year. Amounts are expressed in Swedish kronor (SEK), thousands (TSEK) or millions (SEK million) according to the unit stated.
The parent company applies the same accounting principles as the Group apart from IFRS 16 "Leasing" and with the exceptions and additions that appear in RFR 2 "Accounting for legal entities". The interim report complies with the Annual Accounts Act.
A breakdown by category of the Group's net sales from contracts with customers is presented below:
| Jan-Mar 2023 Jan-Mar 2022 |
||||||||
|---|---|---|---|---|---|---|---|---|
| SEK 000 | Americas | EMEA | APAC | Total | Americas | EMEA | APAC | Total |
| Goods | 128,670 | 19,035 | 21,167 | 168,872 | 109,446 | 29,277 | 13,671 | 152,394 |
| Royalty | 2,029 | 918 | — | 2,947 | 1,555 | 769 | — | 2,324 |
| Net sales | 130,699 | 19,953 | 21,167 | 171,819 | 111,001 | 30,046 | 13,671 | 154,718 |


The following table shows the exchange gains and losses from operating activities that are recognized under costof goods sold:
| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Exchange gains operating activities | 987 | 1,732 |
| Exchange losses operating activities | -613 | -1,066 |
| Exchange result operating activities | 374 | 666 |
The following table shows the exchange gains and losses from financing activities that are recognized in the financial results:
| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Exchange gains financing activities | 837 | 815 |
| Exchange losses financing activities | -1,186 | -1,101 |
| Exchange result financing activities | -349 | -286 |
Probi presents certain financial key performance indicators (KPIs) in the interim report that are not defined according to IFRS. Probi believes that these indicators provide valuable supplementary information to investors and the company's management. Since not all companies calculate alternative KPIs in the same way, these are not always comparable to indicators used by other companies. However, these indicators should not be considered as a substitute for financial indicators required in accordance with IFRS. The following alternative KPIs are reported in the interim report:
The operating profit/loss (EBIT) is defined as the profit/loss before financial income, expenses and tax for the periodand is used as a measure of the company's profitability.
| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Net income | 19,274 | 14,019 |
| Income taxes | 4,806 | 3,607 |
| Financial result | -500 | 865 |
| Operating profit (EBIT) | 23,580 | 18,491 |
EBITDA is defined as the operating profit (EBIT) before depreciation and impairment and is used as a measure of the company's profitability.
| Jan-Mar | ||
|---|---|---|
| SEK 000 | 2023 | 2022 |
| Operating profit (EBIT) | 23,580 | 18,491 |
| Depreciation and amortization | 23,686 | 19,787 |
| EBITDA | 47,266 | 38,278 |


Interim report January-March 2023
| Gross margin | Defined as gross profit divided by net sales |
Used to measure product profitability |
|---|---|---|
| EBITDA margin | Defined as EBITDA divided by net sales |
Used to measure the company's profitability before depreciation and impairment of tangible and intangible assets |
| Currency adjusted net sales growth |
Defined as net sales for the year translated at the preceding year's exchange rates divided by the preceding year's net sales |
Used to measure underlying net sales growth |
| RTM | Rolling twelve months. Refers to full-year figure for the last four quarters |
Gives an indication of development without having to wait for the comparative period next year |
| Operating margin | Defined as the operating profit divided by net sales |
Used to measure the company's profitability |
Probi® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.

